Investigational Drug Information for Veliparib
✉ Email this page to a colleague
What is the development status for investigational drug Veliparib?
Veliparib is an investigational drug.
There have been 96 clinical trials for Veliparib.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 30th 2014.
The most common disease conditions in clinical trials are Carcinoma, Breast Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), AbbVie, and AbbVie (prior sponsor, Abbott).
Summary for Veliparib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,171 |
| WIPO Patent Applications | 981 |
| Japanese Patent Applications | 178 |
| Clinical Trial Progress | Phase 3 (2014-09-30) |
| Vendors | 52 |
Recent Clinical Trials for Veliparib
| Title | Sponsor | Phase |
|---|---|---|
| A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer | AbbVie | Phase 1 |
| Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) | AHS Cancer Control Alberta | Phase 2 |
| Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer | Fudan University | Phase 2 |
Clinical Trial Summary for Veliparib
Top disease conditions for Veliparib
Top clinical trial sponsors for Veliparib
US Patents for Veliparib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
